News

Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform.Goal of developing cellular therapies for Huntington’s disease and potentially Parkinson’s, Alzheimer’s and other neurological conditions.Builds on University’s research in neural stem cell transplantation for Huntington’s disease, including safety and…...

First research collaboration for immunotolerance UniverCyteTM technology platform, marking launch of new business development and collaboration strategySecures milestone collaboration in Japan, where cell therapy R&D is advancing rapidly in a favourable regulatory and commercial environmentUniverCyte platform has the potential to deliver…...

Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated…...

NetraMark Corp., a next generation AI + health data technology company and Juvenescence Limited, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human…...

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, issued a letter to shareholders from Michael D. West, PhD, founder and CEO, and Gregory Bailey, MD, Chairman, reflecting on progress…...

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and to increase human longevity, announce the publication…...

LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology uses lymph nodes as bioreactors to regrow…...

Dr. Greg Bailey, CEO of Juvenescence gives an interview to Longevity Technology to discuss his thoughts on the longevity field and future plans for Juvenescence. In the interview, Greg discusses the origins of Juvenescence as well as his belief that…...

Michael Hufford, CEO of Lygenesis, gives an interview to Longevity Technology about the revolutionary Lygenesis technology and their plans for clinical development. Lygenesis' technology will enable the use of patients lymph nodes as bioreactors to regrow functioning ectopic organs to…...

Insilico Medicine, a pioneer in next-generation artificial intelligence technology for drug discovery, recently completes a USD $37 million funding round led by Qiming Venture Partners, joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital,…...

Juvenescence is impressed by Insilico Medicine's recent article in Nature Biotech, highlighting their ability to use deep learning for de novo small-molecule design. They have developed a deep generative model, generative tensorial reinforcement learning (GENTRL) to discover potent inhibitors of discoidin…...

Juvenescence pipeline company AgeX Therapeutics, a biotechnology company focused on therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, Ph.D., and colleagues have authored a paper in the peer-reviewed scientific journal Regenerative Medicine on…...